Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah - Hebrew Medical Center in Jerusalem. He is Director of the National Institute for Psychobiology in Israel, and Editor-in-Chief of the International Journal of Neuropsychopharmacology.
Part I. Introduction: 1. Genes and psychopharmacology: exploring the interface Bernard Lerer; Part II. Clinical Background and Research Design: 2. From pharmacogenetics to pharmacogenomics of psychotropic drug response Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes and psychiatric nosology Thomas A. Ban; 4. Methodological issues in psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6. The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA processing regulation and interindividual variation Colleen M. Niswender and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs and Disorders: 10. Clozapine response and genetic variation in neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W. Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V. Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17. Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug dependence risk factors Joel Gelernter and Henry Kranzler; Part VI. Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy and Vincenzo S. Basile; Part VII. Industry perspectives: 20. Pharmacogenetics in psychotropic drug discovery and development William Z. Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi; Index.